IDEAYA Biosciences Announces First-Patient-In for Phase 1 Combination Study of IDE849, DLL3 TOP1 ADC, and IDE161, PARG Inhibitor, in DLL3 Upregulated Solid Tumor Indications, including SCLC, NETs, NECs, and Melanoma
FPI achieved for first-in-class combination of IDE849 (DLL3 TOP1 ADC) and IDE161 (PARG inhibitor). IDE161 (PARG) induced accumulation of TOP1 lesions enhances the efficacy and durability of TOP1 ADCs in multiple preclinical models IDE849 Phase 1 study advancing globally to determine RP2D,...
CP
cision pr newswire
via Pr Newswire
Updated 1h ago
Source Verification
Corroboration Score: 1This story was independently reported by 1 sources. Click any source to read the original article.
Comments
0 commentsBe respectful and constructive.
Loading comments...
Previous
Why Filipino makeup brands are opening cafés
Next
2026 NFL Mock Draft: Flipping Everything Upside Down
Related Articles
Health
Health
National digital series spotlights evidence-based strategies to achieve type 2 diabetes remission through lifestyle interventions
Pr Newswire-13h ago-1 sources
HealthQ&A: Digital Workforce looks to expand further into the U.S. market
Mobihealthnews-13h ago-1 sources
HealthWant to slow brain aging? Follow this diet, a new study suggests
The Globe and Mail-13h ago-1 sources